


*Supplementary Materials:*



**Figure S1.** Study flow chart.

**Table S1.** Changes of selected CMR and biochemical parameters between renin-angiotensin-aldosterone blocker users and non-users over the 5-year follow-up.

Changes in	RAAS blockers 0 n = 13	RAAS blockers 1 n = 12	P
native T1, ms	4.28 ± 36.5	-8.47 ± 46.8	0.30
ECV, %	0.023 ± 0.025	0.005 ± 0.043	0.073
Galectin-3, ng/mL	<b>1.35 ± 1.90</b>	<b>-1.31 ± 2.07</b>	<b>0.0068</b>
GDF 15, ng/mL	522.8 ± 718.5	221.0 ± 518.8	0.30
sST2, ng/mL	<b>492.37 ± 459.75</b>	<b>82.16 ± 484.61</b>	<b>0.015</b>
hsTnI, ng/L	<b>-2.20 ± 30.73</b>	<b>-3.71 ± 11.01</b>	<b>0.023</b>
NT-proBNP, ng/L	130.30 ± 268.95	32.67 ± 135.25	0.16

RAAS blockers = blockers of renin-angiotensin-aldosterone system; ECV = extracellular volume; hsTnI = high sensitivity troponin I; sST2 = soluble suppression of tumourigenicity2; GDF 15 = growth differential factor 15; NT-proBNP = N-terminal pro-brain natriuretic peptide. Values are means of change ( $\Delta$ )±standard deviation. P for difference between the two groups were calculated using Wilcoxon Two Sample test. P values < 0.05 are in bold.